Agilent Technologies Inc.
A | NYSE
$174.87
-$6.28 (-3.47%)
At close: Oct 30, 2026, 4:00 PM ET
$175.30
+$0.43 (+0.25%)
Pre-market:
Nov 2, 2026, 7:29 AM ET
Company Profile
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
Key Executives
| Name | Position |
|---|---|
| Padraig McDonnell | Chief Executive Officer, President & Director |
| Adam S. Elinoff | Senior Vice President, Chief Financial Officer & Principal Financial Officer |
| August Specht | Senior Vice President & Chief Technology Officer |
| Michael Buckner | Senior Vice President, Chief Legal Officer, & Secretary |
| Angelica Riemann | Senior VP & President of Agilent CrossLab Group |
| Frederick Schwarz | Senior VP, Chief Strategy & Corporate Development Officer |
| Rodney Gonsalves | Vice President of Finance |
| Simon May | Senior VP and President of Life Sciences & Diagnostics Markets Group |
| Tejas Rajeev Savant | Vice President of Investor Relations |
| Tim Downs | VP & Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 23, 2026 | EFFECT | Filing |
| Sep 23, 2026 | 424B3 | Filing |
| Sep 10, 2026 | 4 | Filing |
| Sep 10, 2026 | 3 | Filing |
| Sep 09, 2026 | 4 | Filing |
| Sep 08, 2026 | 8-K | Current Report |
| Sep 01, 2026 | S-4 | Filing |
| Sep 01, 2026 | S-3ASR | Automatic shelf registration statement of securiti... |
| Sep 01, 2026 | 10-Q | Quarterly Report |
| Aug 26, 2026 | 8-K | Current Report |
Agilent Technologies Inc.
| Country | United States |
| IPO Date | Nov 18, 1999 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 18,200 |
| CEO | Padraig McDonnell |
Contact Details
5301 Stevens Creek Boulevard Santa Clara,
California 95051 United States
Stock Details
| Ticker Symbol | A |
| Exchange | NYSE |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 0001090872 |
| CUSIP Number | 00846U101 |
| ISIN Number | US00846U1016 |
| SIC Code | 3826 |
Recent News
- 3 days ago / businesswire.comAgilent to Announce Fourth-Quarter Fiscal Year 2026 Financial Results on Nov. 23
- 4 days ago / seekingalpha.comParnassus Mid Cap Growth Fund: Q3 2026 Performance Review
- 5 days ago / seekingalpha.comCarillon Scout Mid Cap Fund Q3 2026 Portfolio Review
- 6 days ago / businesswire.comAgilent and University of Chicago Launch Center of Excellence for Energy Materials Research
- 10 days ago / seekingalpha.comDividend Champion, Contender, And Challenger Highlights: Week October 25
- 21 days ago / zacks.comIs Agilent Technologies (A) Outperforming Other Medical Stocks This Year?
- 1 month ago / seekingalpha.comDividend Champion, Contender, And Challenger Highlights: Week October 4
- 1 month ago / gurufocus.comA DCF Analysis: Intrinsic Value $120 vs Price $175
- 1 month ago / zacks.comAgilent (A) Up 9.6% Since Last Earnings Report: Can It Continue?
- 1 month ago / seekingalpha.comAgilent Technologies, Inc. (A) Presents at U.S. All Stars Conference Transcript
Add to Watchlist
Select watchlists to add or remove A